Affiliation: University of Munich
- CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter studyMichael Ewers
Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Ludwig Maximilian University, Munich, Bayern, Germany Electronic address
Alzheimers Dement 11:1306-15. 2015..The aim of this study was to test the diagnostic value of cerebrospinal fluid (CSF) beta-amyloid (Aβ1-42), phosphorylated tau, and total tau (tau) to discriminate Alzheimer's disease (AD) dementia from other forms of dementia...
- Cognitive reserve associated with FDG-PET in preclinical Alzheimer diseaseMichael Ewers
Department of Radiology, University of California, San Francisco, CA, USA
Neurology 80:1194-201. 2013..To examine the effect of education (a surrogate measure of cognitive reserve) on FDG-PET brain metabolism in elderly cognitively healthy (HC) subjects with preclinical Alzheimer disease (AD)...
- Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's diseaseMichael Ewers
University of California, VA Medical Center, Center for Neuroimaging of Neurodegenerative Diseases, San Francisco, San Francisco, CA 94121, USA
Neurobiol Aging 33:1599-608. 2012..There was no interaction between CSF signature and diagnosis or apolipoprotein E (ApoE) genotype. In conclusion, lower BMI is indicative of AD pathology as assessed with CSF-based biomarkers in demented and nondemented elderly subjects...
- Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performanceMichael Ewers
Department of Radiology, University of California, San Francisco, San Francisco, CA, USA
Neurobiol Aging 33:1203-14. 2012..5, 77.4))) and TMT-B test (prediction accuracy 64.6% (95% CI (55.5, 73.4%))). In conclusion, short-term conversion to AD is predicted by single marker models to a comparable degree as by multimarker models in amnestic MCI subjects...
- CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjectsMichael Ewers
Department of Radiology, University of California, San Francisco, 94143, USA
Cereb Cortex 22:1993-2004. 2012....
- Mapping 3-year changes in gray matter and metabolism in Aβ-positive nondemented subjectsMiguel Ángel Araque Caballero
Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Ludwig Maximilian University LMU, Munich, Germany Electronic address
Neurobiol Aging 36:2913-24. 2015..In conclusion, abnormally increased levels of Aβ in nondemented subjects were associated with accelerated decline in both GM and glucose metabolism, where both types of neurodegeneration progress in spatially divergent patterns. ..
- Staging Alzheimer's disease progression with multimodality neuroimagingMichael Ewers
Department of Radiology, University of California at San Francisco, San Francisco, USA
Prog Neurobiol 95:535-46. 2011..This will be important in designing effective treatments that target specific underlying disease AD mechanisms...
- Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjectsMichael Ewers
Institute for Stroke and Dementia Research, Klinikum der Universitat Munchen, Ludwig Maximilian University, Munich, Germany Department of Radiology, University of California, San Francisco, CA, USA VA Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA
Neuroimage Clin 4:45-52. 2014..In conclusion, medial temporal and-parietal FDG-PET and executive function show a clinically acceptable accuracy for predicting clinical progression in elderly HC subjects. ..
- Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementiaMichael Ewers
Department of Radiology, University of California San Francisco, San Francisco, CA, USA
Trends Neurosci 34:430-42. 2011..A dynamic sequence model of changes that occur in neuroimaging markers during the different disease stages is presented and the predictive value of multimodal neuroimaging for AD dementia is considered...